Skip to content

Current ratio at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
1.7×+0.6×
Viatris logo
ViatrisVTRS
1.6×-0.1×
PTH
Pelthos Therapeutics Inc.PTHS
2.8×+2.6×
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
2.6×+0.4×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
4.9×+1.9×
Opko Health logo
Opko HealthOPK
3.6×+1.1×

Other financials

Income statement

See full
Revenue$8.6M+72.1%
Gross profit$4.2M+15.1%
Operating income-$32.2M-15.3%
Net income-$45.7M-75.0%
EPS (diluted)-$6.28-178%

Balance sheet

See full
Cash & equivalents$3.4M-42.2%
Total debt$95.4M+130%
Total equity-$249.2M-17.8%
Total assets$293.6M+272%

Cash flow

See full
Operating cash flow-$1.1M-118%
CapEx$33.3K
Free cash flow$920.8K-63.7%

Valuation

See full
Market cap$54.86M+88.4%
Enterprise value$146.86M+120%
P/S1.6×+1.0×

Profitability

See full
Gross margin59.7%-12.3pp
Operating margin-1,034.4%-1,313pp
Net margin-1,162.4%-1,359pp
FCF margin12.2%

Returns & leverage

See full
Return on equity170.9%
Debt / equity0.3×

Where this comes from

Calculated from Scilex Holding Company’s reported figures.

Based on the most recent quarter.

The official record: Scilex Holding Company’s 10-Q, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scilex Holding Company's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scilex Holding Company's current ratio?
Scilex Holding Company (SCLX) reported current ratio of 0.1× in Q1 2026.
How has Scilex Holding Company's current ratio changed year-over-year?
Scilex Holding Company's current ratio decreased by 19.7% year-over-year, from 0.1× to 0.1×.
What is the long-term trend for Scilex Holding Company's current ratio?
Over 5 years (2020 to 2025), Scilex Holding Company's current ratio has grown at a -14.0% compound annual growth rate (CAGR), from 0.2× to 0.1×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.